Image by Getty Images via Daylife
After Barack Obama’s victory in the U.S. presidential elections, the economic community, in the middle of a recession and the worst financial crisis in the past decades, continues to hold its breath. The Democrat’s victory induce change and potentially more difficult times for the energy, pharmaceutical, telecommunications, and defense sectors, while the biotechnology and alternative energy sectors could be strengthened by the outcome of the elections. Obama has promised to increase investments in wind and solar energy and to spend 150 billion dollars in 10 years to hasten the development of
Doctors may soon be able to ‘draw’ new bone, skin and muscle on to patients, after scientists created a pen-like device that can apply human cells directly on to seriously injured people.
The device contains stem cells and growth factors and will give surgeons greater control over where the materials are deposited.
It will also reduce the time the patient is in surgery by delivering live cells and growth factors directly to the site of injury, accelerating the regeneration of functional bone and cartilage, scientists said.
Call it pork in a petri dish – a technique to turn pig stem cells into strips of meat that scientists say could one day offer a green alternative to raising livestock and help alleviate world hunger.
Dutch scientists have grown pork in the laboratory since 2006, and while they haven’t gotten the texture right or even tasted the meat, they say the technology promises to have widespread implications for the food supply.
“If we took the stem cells from one pig and multiplied it by a factor of a million, we would need 1 million fewer pigs to get the
Image via Wikipedia
Is there a future for stem cell therapies that don’t use embryonic stem cells? An international study involving EPFL has raised doubts, by showing that “reprogramming” adult stem cells leads to genetic aberrations.
It’s a discordant note in the symphony of good news that usually accompanies stem cell research announcements. Stem cells hold enormous promise in regenerative medicine, thanks to their ability to regenerate diseased or damaged tissues. They have made it possible to markedly improve the effectiveness of many medical treatments – muscle regeneration in cases of dystrophy, skin grafts for treating burn victims, and the
StemCells Inc. today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical trial of the Company’s proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD), the most common form of AMD. AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million people worldwide are afflicted with the disease. There are no approved treatments for dry AMD.
“With the approval of this trial, we have accomplished something truly unique in the stem cell field, which